Insider Selling: Insmed (NASDAQ:INSM) COO Sells 802 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 802 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $175.07, for a total transaction of $140,406.14. Following the sale, the chief operating officer directly owned 109,660 shares of the company’s stock, valued at $19,198,176.20. The trade was a 0.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $358,616.03.
• On Tuesday, January 6th, Roger Adsett sold 1,429 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $247,688.57.

Insmed Trading Down 3.3%

Shares of Insmed stock traded down $5.73 during trading on Thursday, reaching $170.27. 2,588,589 shares of the stock were exchanged, compared to its average volume of 2,142,398. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The firm has a market cap of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The stock’s fifty day moving average is $190.79 and its 200 day moving average is $151.24.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. During the same period in the previous year, the company earned ($1.27) EPS. The company’s revenue for the quarter was up 52.4% on a year-over-year basis. As a group, equities research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on INSM shares. Citigroup reaffirmed an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Rothschild Redb raised Insmed to a “strong-buy” rating in a research report on Thursday, December 4th. Mizuho set a $212.00 target price on Insmed in a report on Thursday, December 18th. Morgan Stanley set a $157.00 target price on Insmed in a research report on Thursday. Finally, Wolfe Research set a $167.00 price target on Insmed and gave the company an “outperform” rating in a research report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $205.64.

Hedge Funds Weigh In On Insmed

Several large investors have recently made changes to their positions in INSM. Chung Wu Investment Group LLC purchased a new stake in shares of Insmed in the 2nd quarter worth approximately $173,000. Resolute Capital Asset Partners LLC purchased a new stake in shares of Insmed in the second quarter worth $2,748,000. Caxton Associates LLP bought a new position in Insmed in the 1st quarter worth about $441,000. Assenagon Asset Management S.A. increased its stake in Insmed by 84.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock valued at $7,387,000 after purchasing an additional 33,626 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in Insmed in the second quarter worth about $5,578,000.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.